drugset / Trial / NCT07158918
ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors
RandomizedSequentialOpen-labelTreatment
Summary
This study is to assess the safety and antitumor activity of ABL103 plus pembrolizumab, with or without taxane, in advanced or metastatic solid tumors.
Timeline
- Start
- 2025-08-06
- Primary completion
- 2027-12-02
- Completion
- 2027-12-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABL103 | Unknown | — | Intravenous |
| Background | Pembrolizumab | Monoclonal antibody | — | Intravenous |